Integra LifeSciences Holdings Total Liabilities
Integra LifeSciences Holdings total liabilities. Based on the latest financial reports, Integra LifeSciences Holdings (IART) has total liabilities worth $2.54 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Integra LifeSciences Holdings to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Integra LifeSciences Holdings (1995–2025)
Total liabilities of Integra LifeSciences Holdings from 1995 to 2025. This chart illustrates how Integra LifeSciences Holdings's total liabilities have evolved over time, based on quarterly financial data. Explore IART long-term investment intensity to see how much of total assets are deployed in long-term investments.
Integra LifeSciences Holdings Competitors by Total Liabilities
The table below lists competitors of Integra LifeSciences Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Refrigeration Electrical Engineering Corp
VN:REE
|
Vietnam | ₫15.52 Trillion |
|
Zhongli Science and Technology Group Co Ltd
SHE:002309
|
China | CN¥2.91 Billion |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
Indonesia | Rp6.08 Trillion |
|
Invisio Communications AB
ST:IVSO
|
Sweden | Skr432.90 Million |
|
Zhuhai Orbita Control Eng
SHE:300053
|
China | CN¥800.68 Million |
|
AS LHV GROUP EO -10
F:ASU0
|
Germany | €8.89 Billion |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
China | CN¥1.47 Billion |
|
Hyundai Development Co
KO:294870
|
Korea | ₩4.23 Trillion |
Liability Composition Analysis (1995–2025)
This chart breaks down Integra LifeSciences Holdings's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IART total assets.
Liquidity & Leverage Metrics
Integra LifeSciences Holdings Total Liabilities Ratios Explained
Integra LifeSciences Holdings total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Integra LifeSciences Holdings's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Integra LifeSciences Holdings (1995–2025)
The table below shows the annual total liabilities of Integra LifeSciences Holdings from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.56 Billion | +2.66% |
| 2024-12-31 | $2.49 Billion | +13.58% |
| 2023-12-31 | $2.19 Billion | +5.21% |
| 2022-12-31 | $2.09 Billion | -0.58% |
| 2021-12-31 | $2.10 Billion | -0.13% |
| 2020-12-31 | $2.10 Billion | +11.33% |
| 2019-12-31 | $1.89 Billion | +8.91% |
| 2018-12-31 | $1.73 Billion | -22.98% |
| 2017-12-31 | $2.25 Billion | +132.26% |
| 2016-12-31 | $968.29 Million | -5.37% |
| 2015-12-31 | $1.02 Billion | +17.04% |
| 2014-12-31 | $874.30 Million | +66.20% |
| 2013-12-31 | $526.05 Million | -18.55% |
| 2012-12-31 | $645.82 Million | -0.87% |
| 2011-12-31 | $651.47 Million | +25.93% |
| 2010-12-31 | $517.35 Million | +4.47% |
| 2009-12-31 | $495.22 Million | -27.62% |
| 2008-12-31 | $684.23 Million | +22.71% |
| 2007-12-31 | $557.58 Million | +75.64% |
| 2006-12-31 | $317.46 Million | +100.14% |
| 2005-12-31 | $158.61 Million | +6.53% |
| 2004-12-31 | $148.89 Million | +3.40% |
| 2003-12-31 | $144.00 Million | +431.92% |
| 2002-12-31 | $27.07 Million | +15.04% |
| 2001-12-31 | $23.53 Million | -28.11% |
| 2000-12-31 | $32.73 Million | +15.66% |
| 1999-12-31 | $28.30 Million | +757.58% |
| 1998-12-31 | $3.30 Million | +26.92% |
| 1997-12-31 | $2.60 Million | +13.04% |
| 1996-12-31 | $2.30 Million | +15.00% |
| 1995-12-31 | $2.00 Million | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more